Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

mCRPC 1Turcot syndrome 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Neoplasm Metastasis 1Insulin-Like Growth Factor I, Resistance To 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × mCRPC × tislelizumab × Clear all
NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡